This trial is evaluating whether Treatment will improve 1 primary outcome, 5 secondary outcomes, and 1 other outcome in patients with Type 1 Diabetes Mellitus. Measurement will happen over the course of 12 weeks for each arm of the crossover.
This trial requires 90 total participants across 3 different treatment groups
This trial involves 3 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"Although autoimmune beta-cell failure is thought to occur early in autoimmune diabetes, as most patients have the disease for quite some time, the only real therapy for autoimmune diabetes is insulin pump therapy, at which the disease can be suppressed." - Anonymous Online Contributor
"Diabetic patients typically have a higher rate of psychiatric complications, which may in part be related to glycemic control. Thus, effective therapy in this subset of patients is likely to influence outcome for both diabetes and depression. Copyright © 2015 John Wiley & Sons, Ltd. Diabetes mellitus type 2." - Anonymous Online Contributor
"There is a strong association between autoimmunity and diabetes. However, one cannot infer from the presence of an autoimmune disease that diabetes is the result of a disorder in the autoimmune process." - Anonymous Online Contributor
"About 18.5 million Americans are likely to be affected by Diabetes in the year 2002, as most of them have no known risk factor. Of total number of Diabetes population, about 7.5 million are predicted to be affected in year 2020." - Anonymous Online Contributor
"As a group, those with diabetes display a greater prevalence of autoimmune diseases, such as diabetes autoantibodies and increased prevalence of insulin-dependent diabetes compared to normal subjects. In addition, there appears to be a marked increase of autoantibodies of diabetes in female." - Anonymous Online Contributor
"Diabetes with autoantibodies to insulin can be the first clinical presentation of diabetes with significant hyperglycemia and many patients with diabetes may be diagnosed at the time of presentation with diabetes and not first with DM1. Diabetics and healthy controls have an increased risk for islet cell autoantibodies, and hence a strong association exists with type 1 diabetes." - Anonymous Online Contributor
"The common side effects of treatment , as measured by the Mayo Clinic, for [diabetes type 1](https://www.withpower.com/clinical-trials/diabetes-type-1) and autoimmune diabetes are (1) headaches [70%],  muscle aches [45%], and (3) joints, back, and muscle pain [46%]. The common side effects of treatment , as measured per the Mayo Clinic's database, for type 2 are  headaches [53%],  fatigue and (6) weight gain." - Anonymous Online Contributor
"Autoimmune and genetic causes of type 1 and type 2 diabetes, along with metabolic and lifestyle risk factors, make up the bulk of the risk for type 2 diabetes in our cohort. The metabolic effects of high BMI and poor diet may amplify the genetic risk. Genetic risk in those who are of Scandinavian ancestry is especially high, indicating that genetic factors are of major importance in the risk for type 2 diabetes in this population." - Anonymous Online Contributor
"Clinicians from all backgrounds and all specialties and many subspecialties of medicine are prescribing therapies for diabetes, autoimmune conditions, and both of these conditions on a daily basis and are prescribing treatments for other conditions which are of clinical concern to patients. Given that these practitioners have a greater expertise than patients/guardians in the management of diabetes and autoimmune conditions, clinical trials for diabetes are likely to receive high levels of attention from clinical practitioners. However, there is a significant paucity of clinical trials for diabetes in general and specifically for autoimmune conditions in patients/guardians. Therefore, clinicians and investigators need to generate clinical trials. The need for clinical trials for diabetes and autoimmune indications is high and will rise in the coming years." - Anonymous Online Contributor
"Most patients received drugs for a variety of reasons. Diabetes was the most frequently reported reason for use of other drugs. These drugs, which were not reported as being used typically in treatment, may influence the outcome of patients with diabetes in an adverse way." - Anonymous Online Contributor
"Diabetes is becoming a problem in the older population. People with diabetes and autoimmune conditions had earlier diagnoses and more comorbidities than those with diabetes alone. The most common age of diagnosis was 65 years old in patients with diabetes alone, while those with autoimmune conditions had older diagnoses (58.5 years old) and more comorbidities (6.5 comorbidities). There is a need to educate people with diabetes and autoimmune conditions to help improve their earlier diagnosis." - Anonymous Online Contributor
"The majority of patients (64%) were responsive to one treatment regimen, suggesting that drug therapy is highly effective for long-term control of hyperglycemia. Long-term drug therapy also reduces the risk of developing diabetes and retinopathy in a substantial proportion of patients (29% and 23% respectively)." - Anonymous Online Contributor